Talwar Dhruv, Kumar Sunil, Acharya Sourya, Hulkoti Vidyashree, Annadatha Akhilesh
Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Wardha, IND.
Cureus. 2021 Aug 11;13(8):e17102. doi: 10.7759/cureus.17102. eCollection 2021 Aug.
Immunocompromised status Is often associated with severe coronavirus infection given the inability of the immune system to combat the deadly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with multiple comorbidities such as diabetes mellitus, hypertension, and chronic kidney disease along with patients on immunosuppressants or chemotherapy are at higher risk of getting infected during the ongoing pandemic with more probability of adverse outcomes. However, we report a rare case of a renal transplant recipient who was on sirolimus and contracted coronavirus disease (COVID-19). His immunosuppressants were continued and he was managed with antiviral, steroids and low molecular weight heparin and the patient responded well to the treatment and recovered completely after a span of one week. Use of sirolimus in a patient with renal transplant recipient helped in preventing intensification of the severity in COVID-19 attributing to its inhibiting effect on mammalian target of rapamycin (mTOR) which he was using post his renal transplant, therefore, proving to be a blessing in disguise.
鉴于免疫系统无法对抗致命的严重急性呼吸综合征冠状病毒2（SARS-CoV-2），免疫功能低下状态常与严重的冠状病毒感染相关。患有多种合并症（如糖尿病、高血压和慢性肾病）的患者，以及正在服用免疫抑制剂或接受化疗的患者，在当前大流行期间感染的风险更高，出现不良后果的可能性也更大。然而，我们报告了一例罕见病例，一名肾移植受者正在服用西罗莫司，感染了冠状病毒病（COVID-19）。他继续服用免疫抑制剂，并接受了抗病毒药物、类固醇和低分子量肝素治疗，患者对治疗反应良好，一周后完全康复。肾移植受者使用西罗莫司有助于预防COVID-19病情加重，这归因于其对肾移植后使用的雷帕霉素哺乳动物靶点（mTOR）的抑制作用，因此，这证明是因祸得福。
